Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 9, 2017, Pages 709-717

  Birkeland, Kåre I ^a,b   Jørgensen, Marit E ^c,d   Carstensen, Bendix ^c   Persson, Frederik ^c   Gulseth, Hanne L ^b   Thuresson, Marcus ^e   Fenici, Peter ^f   Nathanson, David ^g   Nyström, Thomas ^g   Eriksson, Jan W ^h   Bodegård, Johan ^f   Norhammar, Anna ^g,i  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c STENO DIABETES CENTER   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e STATISTICON AB   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; SWEDEN; AGED; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; COMPLICATION; MIDDLE AGED; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MORBIDITY; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85028078375     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30258-9     Document Type: Article

References (28)

1. Norhammar, A, Bodegård, J, Nyström, T, Thuresson, M, Eriksson, JW, Nathanson, D, Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013. Diabetologia 59 (2016), 1692–1701.
2. Green, JB, Bethel, MA, Armstrong, PW, et al., for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
3. Scirica, BM, Bhatt, DL, Braunwald, E, et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
4. White, WB, Cannon, CP, Heller, SR, et al., for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
5. Zinman, B, Wanner, C, Lachin, JM, et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
6. Neal, B, Perkovic, V, Mahaffey, KW, et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 published online June 12. DOI:10.1056/NEJMoa1611925.
7. Sonesson, C, Johansson, PA, Johnsson, E, Gause-Nilsson, I, Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol, 15, 2016, 37.
8. Wu, JH, Foote, C, Blomster, J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
9. Kosiborod, M, Cavender, MA, Fu, AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation, 2017 published online May 18. DOI:10.1161/CIRCULATIONAHA.117.029190.
10. Cavender, M, Norhammar, A, Birkeland, KI, et al., on behalf of the CVD-REAL Investigators and Study Group. Hospitalization for heart failure and death in new users of SGLT2 inhibitors in patients with and without cardiovascular disease: CVD-REAL Study. Diabetes 66:suppl 1 (2017), A99–100 (abstract 377-OR).
11. Eriksson, JW, Bodegard, J, Nathanson, D, Thuresson, M, Nystrom, T, Norhammar, A, Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract 117 (2016), 39–47.
12. Nyström, T, Bodegard, J, Nathanson, D, Thuresson, M, Norhammar, A, Eriksson, JW, Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 123 (2017), 199–208.
13. Sekhon, JS, Multivariate and propensity score matching software with automated balance optimization. J Stat Softw 7 (2011), 1–52.
14. Normand, ST, Landrum, MB, Guadagnoli, E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54 (2001), 387–398.
15. Andersen, PK, Keiding, N, Interpretability and importance of functionals in competing risks and multistate models. Stat Med 31 (2012), 1074–1088.
16. R Development Core Team. R: a language and environment for statistical computing, 2015, R Foundation for Statistical Computing, Vienna.
17. Nyström, T, Bodegard, J, Nathanson, D, Thuresson, M, Norhammar, A, Eriksson, JW, Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients. Diabetes Obes Metab 19 (2017), 831–841.
18. Zoungas, S, Patel, A, Chalmers, J, et al., for the ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 (2010), 1410–1418.
19. Bertoni, AG, Hundley, WG, Massing, MW, Bonds, DE, Burke, GL, Goff, DC Jr, Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 (2004), 699–703.
20. Boonman-de Winter, LJ, Rutten, FH, Cramer, MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 55 (2012), 2154–2162.
21. Johansson, I, Dahlström, U, Edner, M, Näsman, P, Rydén, L, Norhammar, A, Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol 68 (2016), 1404–1416.
22. Fitchett, D, Zinman, B, Wanner, C, et al., on behalf of the EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
23. Rydén, L, Grant, PJ, Anker, SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
24. Ludvigsson, JF, Andersson, E, Ekbom, A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
25. Sundbøll, J, Adelborg, K, Munch, T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open, 6, 2016, e012832.
26. Ingelsson, E, Arnlöv, J, Sundström, J, Lind, L, The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7 (2005), 787–791.
27. Kümler, T T, Gislason, GH, Kirk, V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 10 (2008), 658–660.
28. Brynildsen, J, Høiseth, AD, Nygård, S, et al. Diagnostic accuracy for heart failure—data from the Akershus Cardiac Examination 2 Study. Tidsskr Nor Laegeforen 135 (2015), 1738–1744 (in Norwegian).